GLP-1 Drug Development
Latest in GLP-1 Drug Development· Nov 9
Eli Lilly's Foundayo reduced obstructive sleep apnea in phase 3 testing, a secondary outcome that expands the drug's addressable market beyond weight loss. Sleep apnea affects a large share of obese patients and carries separate treatment costs; dual efficacy strengthens the case for insurance coverage and widens the patient population eligible for the drug. The finding positions Foundayo to capture a second major indication within Lilly's obesity franchise.
Clinical development, competitive landscape, and market dynamics of GLP-1 receptor agonist medications and related obesity/diabetes drug combinations.
7 events tracked
- Single source2 days ago
Eli Lilly's Foundayo reduces sleep apnea in late-stage testing
Eli Lilly will seek U.S. approval by year-end for its daily obesity pill to treat moderate-to-severe obstructive sleep apnea in obese adults.
CNBC
- Single source16 days ago
Moderna cancer vaccine enthusiasm wanes as Phase 3 data disappoints
Investor enthusiasm for Moderna's cancer vaccine candidate is waning.
MarketWatch
- Single source18 days ago
Biotech rally draws investors seeking exposure to drug innovation wave
Biotech stocks are rising on optimism about new drug innovation.
CNBC
- Single source18 days ago
Amgen drug reduces mortality 58% when paired with AstraZeneca immunotherapy
Amgen reports its drug combination reduces mortality risk by 58% in aggressive lung cancer patients.
CNBC
- Single source23 days ago
Novo's experimental obesity injection produces quarter bodyweight reduction in women
Novo disclosed that CagriSema, an experimental injection, achieved greater weight reduction than its existing Wegovy treatment in late-stage testing.
CNBC
- Single sourceabout 1 month ago
Eli Lilly and Novo Nordisk pursue amylin-based treatments for obesity
Eli Lilly and Novo Nordisk are developing amylin-based obesity drugs to follow their GLP-1 successes.
CNBC
- Single sourceabout 1 month ago
Eli Lilly's dual-drug obesity treatment demonstrates stronger weight reduction in Phase 2
Eli Lilly's combination obesity treatment shows improved weight loss results in mid-stage trial.
CNBC